- ICH GCP
- EU-register voor klinische proeven
Laatste proeven
EudraCT Number: 2006-002161-39 | Sponsor Protocol Number: CV185-034 | Start Date: 2006-12-05 | ||||||
Sponsor Name: Bristol-Myers Squibb International Corporation | ||||||||
Full Title: A Phase 3 Randomized, Double-Blind, Active-Controlled (Enoxaparin), Parallel Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Kne... | ||||||||
Medical condition: Subjects undergoing elective total knee replacement surgery | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: DK (Completed) SE (Completed) HU (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2006-000556-41 | Sponsor Protocol Number: 106789 | Start Date: 2006-12-05 | ||||||
Sponsor Name: GlaxoSmithKline Biologicals | ||||||||
Full Title: An open, phase IV, single-group multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B vaccine challenge in children at 4-5... | ||||||||
Medical condition: Antibody persistence and hepatitis B vaccine challenge in children at 4-5 years of age, previously primed and boosted with 4 doses of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine in routine vaccinatio... | ||||||||
|
||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||
Trial protocol: DE (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2006-005772-41 | Sponsor Protocol Number: LIMIT phase 2 version 1.0 | Start Date: 2006-12-05 | |||||||||||
Sponsor Name: investigator-driven research: Erasmus MC, Neurovascular Section | |||||||||||||
Full Title: LIMIT: Lowering the Incidence of vascular complications with Metformin in patients with Impaired glucose tolerance and a recent TIA or minor ischemic stroke: a phase 2, randomized, controlled trial | |||||||||||||
Medical condition: Patients with impaired glucose tolerance and a recent TIA or minor ischemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004432-70 | Sponsor Protocol Number: ema1-profilC-2006 | Start Date: 2006-12-04 | |||||||||||
Sponsor Name: AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA | |||||||||||||
Full Title: A multicenter phase II study to evaluate the safety, tolerability and efficacy of caspofungin as prophylactic treatment of invasive fungal infections in patients with acute leukemia undergoing ind... | |||||||||||||
Medical condition: neutropenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003561-13 | Sponsor Protocol Number: cro488 | Start Date: 2006-12-04 | ||||||
Sponsor Name: imperial college | ||||||||
Full Title: Reversal of steroid insensitivity in COPD by theophylline | ||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: GB (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2006-003149-17 | Sponsor Protocol Number: NSCLC-TRT-Avastin | Start Date: 2006-12-04 | ||||||
Sponsor Name: VU University Medical Center | ||||||||
Full Title: Phase I study of concurrent with involved-field thoracic radiotherapy for inoperable non-squamous cell lung cancer, followed by both concurrent and maintenance Bevacizumab | ||||||||
Medical condition: Patients with locally advanced (stages II-IIIB) non-small cell lung cancer who are eligible for high-dose radiotherapy following the completion of induction systemic chemotherapy. | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: NL (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002832-10 | Sponsor Protocol Number: FOXA-1 | Start Date: 2006-12-04 | ||||||
Sponsor Name: Haukeland University Hospital | ||||||||
Full Title: Liitännäishoitona annetun oksaliplatiinipohjaisen solusalpaajahoidon jälkeinen hedelmällisyys kolorektaalisyöpäpotilailla. Pohjoismainen prospektiivinen tutkimus. Fertility in colorectal cancer pat... | ||||||||
Medical condition: Kolorektaalisyöpä, colorectal cancer | ||||||||
|
||||||||
Population Age: Adults | Gender: Male, Female | |||||||
Trial protocol: FI (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001763-36 | Sponsor Protocol Number: CSPP100A2347 | Start Date: 2006-12-04 | ||||||
Sponsor Name: Novartis Pharma Services AG | ||||||||
Full Title: A randomized, double-blind, parallel-group, placebo-controlled, multinational clinical trial to evaluate the efficacy of Aliskiren and valsartan versus placebo in lowering levels on NT-proBNP in st... | ||||||||
Medical condition: Hypertension | ||||||||
|
||||||||
Population Age: | Gender: Male, Female | |||||||
Trial protocol: NL (Completed) SE (Completed) CZ (Completed) BE (Completed) DE (Completed) HU (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2006-004632-69 | Sponsor Protocol Number: P060309 | Start Date: 2006-12-04 | |||||||||||
Sponsor Name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Polymorphismes du gène codant pour le cytochrome 2C19 et réponse au clopidogrel chez le sujet sain | |||||||||||||
Medical condition: volontaire sain | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002060-26 | Sponsor Protocol Number: 1401201 | Start Date: 2006-12-04 | |||||||||||
Sponsor Name: Intendis GmbH | |||||||||||||
Full Title: A double-blind, randomized, vehicle-controlled, 6-week exploratory multicenter pilot study of the efficacy and safety of Azelaic Acid (AzA) 15% gel in the topical treatment of mild to moderate seb... | |||||||||||||
Medical condition: Patients with mild to moderate seborrheic dermatitis of the facial area and meeting the specific eligibility criteria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |